General Information of the Drug (ID: M6APDG03825)
Name
PF-04840082
Status
Phase 1
TTD Drug ID
D04OMR
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Dickkopf-related protein 1 (DKK1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
Response Summary Dickkopf-related protein 1 (DKK1) is a therapeutic target for PF-04840082. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of PF-04840082 through regulating the expression of Dickkopf-related protein 1 (DKK1). [1], [2]
References
Ref 1 The m6A(m)-independent role of FTO in regulating WNT signaling pathways. Life Sci Alliance. 2022 Feb 15;5(5):e202101250. doi: 10.26508/lsa.202101250. Print 2022 May.
Ref 2 Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 9;114(2):371-9. doi: 10.1182/blood-2008-11-191577. Epub 2009 May 5.